Bisphosphonates for prevention of postmenopausal osteoporosis

Danish Medical Bulletin

Volumn 49, Issue 1, 2002, Pages 1-18

  Ravn, Pernille ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; IBANDRONIC ACID; OSTEOCALCIN; PEPTIDE DERIVATIVE; PLACEBO;

BLOOD LEVEL; BODY FAT; BONE ATROPHY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PREMENOPAUSE; PROTEIN URINE LEVEL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TREATMENT OUTCOME;

ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0036174851     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (209)

1. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
2. The effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
3. The economic and human costs of osteoporotic fracture
4. Early postmenopausal diminution of forearm and spinal bone mineral density: A cross-sectional study
5. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women
6. Axial and appendicular bone density predict fractures in older women
7. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
8. Bone mineral content of the femoral neck and shaft: Relation between cortical and trabecular bone
9. Immunoassay for quantifying type I collagen degradation products in urine evaluated
10. Dose-response relationships for alendronate treatment in osteoporotic elderly women
11. Calcium-enriched foods and bone mass growth in prepubertal girls: A randomized, double-blind, placebo-controlled trial
12. Single x-ray absorptiometry: Performance characteristics and comparison with single photon absorptiometry
13. Focal osteomalacia due to low-dose disphosphonate therapy in Paget's disease
14. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
15. Vitamin D3 and calcium to prevent hip fractures in elderly women
16. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
17. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
18. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
19. Intra-individual variation and response to anti-resorptive therapy assessed by bone resorption measurements with the Serum Cross-Laps One Step ELISA
20. Clinical evaluation of the Serum Cross-Laps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides
21. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy
22. Serum alkaline phosphatase during hormone treatment in early postmenopausal women. A model for establishing optimal prophylaxis land treatment in postmenopausal osteoporosis
23. Prediction of rapid bone loss in postmenopausal women
24. 17β-estradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women
25. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
26. Who are candidates for prevention and treatment of osteoporosis?
27. Can we improve compliance with long-term HRT?
28. Lifetime risks of hip, Colles' or vertebral fracture and coronary heart disease among white postmenopausal women
29. Bone density at various sites for prediction of hip fractures
30. HRT: An analysis of benefits, risks and costs
31. A controlled trial of the effect of calcium supplementation one bone density in postmenopausal women
32. Calcium supplementation and bone loss: A review of controlled clinical trials
33. Esophagitis associated with the use of alendronate
34. Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss
35. Biochemical markers of bone turnover
36. The role of markers of bone turnover in the assessment of fracture risk in postmenopausal women
37. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
38. Ibandronate
39. Treatment of postmenopausal osteoporosis
40. Relation between body size and bone mineral density in elderly men and women
41. Bone strength: The bottom line
42. Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures
43. The cartilage collagens - Analysis of their cross-linking interactions and matrix organisation
44. The cartilage collagens: Structural and metabolic studies
45. Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy
46. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha 1) region
47. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo
48. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease
49. 45Ca kinetics in the intact rat
50. Bisphosphonates: Mechanism of action
51. Total bone calcium in normal women: Effect of age and menopause status
52. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
53. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease
54. Decreased bone turnover in oral contraceptive users
55. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective study
56. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
57. Noninvasive assessment of bone mineral and structure: State of the art
58. Comparison of urinary bone resorption markers in women of 40-70 years; day-to-day and long-term variation in individual subjects
59. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine
60. Studies of the oral bioavailability of alendronate
61. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss
62. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis
63. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis
64. Hormone therapy to prevent disease and prolong life in postmenopausal women
65. Ibandronate treatment in Paget's disease of bone
66. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
67. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
68. Predicting various fragility fractures in women by forearm bone densitometry: A follow-up study
69. Potential risk factors for development of postmenopausal osteoporosis - Examined over a 12-year period
70. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 Year study
71. Is heritability a risk factor for postmenopausal osteoporosis?
72. Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women
73. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
74. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
75. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
76. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone
77. Bisphosphonate effects and the bone remodeling transient
78. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss
79. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, doubleblind, placebo-controlled study
80. Prospective trial of oestrogen and calcium in postmenopausal women
81. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
82. Evidence that increased calcium intake does not prevent early postmenopausal bone loss
83. Age and bone mass as predictors of fracture in a prospective study
84. The socioeconomic burden of fractures: Today and in the 21st century
85. Calcium supplementation and increases in bone mineral density in children
86. Progressive loss of bone in the femoral neck in elderly people: Longitudinal findings from the Dubbo osteoporosis epidemiology study
87. Comparison of analytical performance and biological variability of three bone resorption assays
88. Osteoporosis and osteopenia
89. The diagnosis of osteoporosis
90. Rationale for the use ofalendronate in osteoporosis
91. Prevention of non-vertebral fractures by alendronate. A meta-analysis
92. Age- and menopause-related changes in indices of bone turnover
93. Single x-ray absorptiometry of the forearm. Precision, correlation, and reference data
94. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate
95. Bone remodeling and calcium metabolism: A correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's disease
96. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
97. Esophagitis and alendronate
98. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals
99. Renal handling of alendronate in rats. An uncharacterized renal transport
100. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment
101. Prevention of spinal osteoporosis in oophorectomised women
102. The minimum effective dose of estrogen for prevention of postmenopausal bone loss
103. Estrogen treatment of patients with established osteoporosis
104. Bone mass and body composition in normal women
105. Treatment of postmenopausal osteoporosis with transdermal estrogen
106. First- and second-year effects in trials of calcium supplementation on the loss of bone density in postmenopausal women
107. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
108. Cyclic etidronate: Has the rose lost its bloom?
109. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones
110. Spine and femur density using dual-photon absorptiometry in US white women
111. Bone density in premenopausal women: Effects of age, dietary intake, physical activity, smoking and birth-control pills
112. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial
113. Epidemiology of age-related fractures
114. Biomechanical aspects of fracture
115. Perspective: How many women have osteoporosis?
116. Longterm fracture prediction by bone mineral assessed at different skeletal sites
117. Relationship of bone turnover to bone density and fractures
118. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)
119. Serum osteocalcin and bone mineral density at various skeletal sites: A study performed with three different assays
120. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause?
121. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs
122. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
123. Sex differences in age-related loss of vertebral trabecular bone mass and structure - Biomechanichal consequences
124. Alkaline phosphatase isoenzymes
125. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: A double blind placebo controlled study
126. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption
127. Bone composition in the distal forearm
128. The proportion of trabecular bone in human vertebrae
129. Differences in axial bone mineral density, serum levels of sex steroids, and bone metabolism between postmenopausal and age- and body size-matched premenopausal subjects
130. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis
131. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
132. Biological variation in bone-derived biochemical markers in serum
133. The coupling of bone formation to resorption: A critical analysis of the concept and its relevance to the pathogenesis of osteoporosis
134. Relationship between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss
135. Age-related structural changes in trabecular and cortical bone: Cellular mechanisms and biomechanical consequences
136. Trabecular bone architecture in the pathogenesis and prevention of fracture
137. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
138. Origin of the vitamin K-dependant bone protein found in plasma and its clearance by kidney and bone
139. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone replacement therapy
140. Dose-response study of ibandronate in the treatment of cancerassociated hypercalcaemia
141. Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy X-ray absorptiometry
142. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
143. High bone turnover is associated with low bone mass in both pre- and postmenopausal women
144. Comparison of bone densitometry of the phalanges, distal forearm and axial skeleton in early postmenopausal women participating in the EPIC study
145. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women
146. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment
147. Bone densitometry: A new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment
148. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the Early Postmenopausal Intervention Cohort Study. A randomized, controlled trial
149. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women
150. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
151. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the Early Postmenopausal Intervention Cohort Study
152. Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal
153. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
154. Prevention of postmenopausal bone loss by tiludronate
155. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
156. The prevention and treatment of osteoporosis
157. Does calcium potentiate the effect of estrogen therapy on postmenopausal bone loss
158. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study
159. Biochemical markers of bone turnover. II: Diagnosis, prophylaxis and treatment of osteoporosis
160. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy
161. Preclinical pharmacology of alendronate
162. Premenopausal bone loss in the lumbar spine and neck of femur: A study of 225 Caucasian women
163. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
164. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates
165. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy
166. Measurement of a more stable region ofosteocalcin in serum by ELISA with two monoclonal antibodies
167. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
168. A critical review of bone mass and the risk of fractures in osteoporosis
169. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis
170. The influence of pyrophosphate, condensed phosphates, phosphonates, and other phosphate compounds on the dissolution ofhydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats
171. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis
172. Bisphosphonates act on rat bone resorption through the mediation ofosteoblasts
173. Computer modeling and analysis of cross-sectional bone density studies with respect to age and the menopause
174. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
175. The distribution of cortical and trabecular bone mass along the lengths of the radius and ulna and the implications for in vivo bone mass measurements
176. Reduced bone mass in daughters of women with osteoporosis
177. Biochemical parameters associated with low bone density in healthy men and women
178. Structure-activity relationships of various bisphosphonates
179. Antiresorptive doseresponse relationships across three generations of bisphosphonates
180. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: Age- and sex-related changes and reference limits
181. Radial bone mineral density in pre- and perimenopausal women: A prospective study of rates and risk factors for loss
182. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study
183. Rossing MA Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
184. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women
185. Age-related decrements in bone mineral density in women over 65 years of age
186. Determinants of bone density in normal women: Risk factors for future osteoporosis
187. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
188. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
189. Compliance problems with hormone replacement therapy
190. Accuracy of measurement of body composition by dual energy x-ray absorptiometry in vivo
191. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up study
192. Sygdomsmønsteret for indlagte og ambulante patienter i 1995. Sundhedsstyrelsen
193. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
194. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause
195. Variation in lumbar spine and femoral neck bone mineral measured by dual energy x-ray absorption: A study of 329 normal women
196. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD
197. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study
198. Sex- and age-related changes in bone and serum osteocalcin
199. Postmarketing surveillance of the safety of cyclic etidronate
200. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: The EPIDOS study
201. Total and regional body-composition changes in early postmenopausal women: Age-related or menopausal-related?
202. Bone mass measurement prediction of risk
203. Antifracture efficacy of antiresorptive agents are related to changes in bone density
204. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
205. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
206. Alkaline phosphatase and the measurement of bone formation